Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Learn more about:
Related Clinical Trial
Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Xbiotics_RTT) The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Official Title

A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Brief Summary

      To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing
      symptom severity when compared with placebo, in participants with Rett syndrome.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo

Secondary Outcome

 Change From Baseline in the Mean RSBQ Total Score at Week 24 for the 5 mg/kg/Day GWP42003-P Dose Level Compared With Placebo

Condition

Rett Syndrome

Intervention

GWP42003-P

Study Arms / Comparison Groups

 5 milligrams per kilogram per day (mg/kg/day) GWP42003-P
Description:  100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

29

Start Date

July 29, 2019

Completion Date

January 21, 2021

Primary Completion Date

January 21, 2021

Eligibility Criteria

        Key Inclusion Criteria:

          -  Participant (if possessing adequate understanding, in the investigator's opinion)
             and/or their parent(s)/legal representative is willing and able to give informed
             consent/assent for participation in the trial.

          -  Participant and their caregiver are willing and able (in the investigator's opinion)
             to comply with all trial requirements (including the completion of all caregiver
             assessments by the same caregiver throughout the trial).

          -  Participant must weigh at least 10 kilograms.

          -  Clinical diagnosis of Rett syndrome (typical or atypical), defined according to
             RettSearch Consortium criteria

          -  Confirmed pathogenic genetic mutation of the MECP2 gene

          -  Participant must be post-regression (≥ 6 months since last loss of hand use or verbal
             language or gross motor regression).

          -  Participant must have a disease severity of between 10 and 36, defined according to
             the Clinical Severity Scale (CSS).

          -  All medications or interventions (including antiepileptic drugs [AEDs] and
             non-pharmacological interventions - dietary supplements, probiotics, physical therapy,
             speech therapy, etc.) for Rett syndrome-related symptoms must have been stable for 4
             weeks prior to screening and the participant/caregiver must be willing to maintain a
             stable regimen throughout the trial.

          -  Ability to swallow the investigational medicinal product (IMP) provided as a liquid
             solution, or the ability for IMP to be delivered via gastrostomy (G) or nasogastric
             (NG) feeding tube (only G-or NG-tubes made from polyurethane or silicon are allowed)

          -  Participant and/or parent(s)/legal representative is willing to allow the responsible
             authorities to be notified of participation in the trial, if mandated by local law.

          -  Participant and/or parent(s)/legal representative is willing to allow the
             participant's primary care practitioner (if they have one) and consultant (if they
             have one) to be notified of participation in the trial, if the primary care
             practitioner/consultant is different than the investigator.

        Key Exclusion Criteria:

          -  Participant meets exclusion criteria for Rett syndrome diagnosis (traumatic brain
             injury, neurometabolic disease, or severe infection that causes neurological problems;
             grossly abnormal psychomotor development in the first 6 months of life).

          -  Participant has clinically significant abnormal laboratory values, in the
             investigator's opinion.

          -  Participant is taking more than 2 concurrent AEDs.

          -  Any history of suicidal behavior or any suicidal ideation in the last month or at
             screening

          -  Clinically relevant abnormalities in the electrocardiogram (ECG) measured at screening
             or randomization

          -  Concurrent cardiovascular conditions which will, in the investigator's opinion,
             interfere with the ability to assess their ECGs or put the participant at risk because
             of participation in the trial

          -  First or second degree relative with a history of significant ECG abnormalities, in
             the opinion of the investigator (e.g. premature cardiac arrest, sudden death)

          -  Any known or suspected hypersensitivity to cannabinoids or any of the excipients of
             the IMP (active or placebo), such as sesame oil

          -  Participant has moderately impaired hepatic function at screening, defined as alanine
             aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × upper limit of normal
             (ULN) or total bilirubin > 2 × ULN.

          -  Participant is of childbearing potential, unless willing to ensure that they or their
             partner use a highly effective method of birth control (e.g., combined [estrogen and
             progestogen containing] hormonal contraception associated with inhibition of ovulation
             [oral, intravaginal, or transdermal], progestogen-only hormonal contraception
             associated with inhibition of ovulation [oral, injectable, or implantable],
             intrauterine devices/hormone-releasing systems, bilateral tubal occlusion,
             vasectomized partner, sexual abstinence) during the trial and for 3 months thereafter.

          -  Pregnant (positive pregnancy test) or lactating

          -  Received an IMP within the 3 months prior to screening

          -  Participant has been taking felbamate for less than 1 year prior to screening.

          -  Currently using or has used recreational or medicinal cannabis, cannabinoid-based
             medications (including Sativex®), or cannabidiol oral solutions (including CBD-OS
             [GWP42003-P]) within the 3 months prior to screening and is unwilling to abstain for
             the duration of the trial

          -  Participant has a positive delta-9-tetrahydrocannabinol (THC) test at screening.

          -  Any other systemic dysfunction (e.g., gastrointestinal, renal, respiratory) or
             significant disease or disorder which, in the opinion of the investigator, may either
             put the participant at risk because of participation in the trial, may influence the
             result of the trial, or the participant's ability to participate in the trial

          -  Any abnormalities identified following a physical examination of the participant that,
             in the opinion of the investigator, would jeopardize the safety of the participant if
             she took part in the trial

          -  Participant has been previously randomized into this trial.

          -  Participant has traveled outside the country of residence planned during the trial.
      

Gender

All

Ages

2 Years - 18 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Italy

Location Countries

Italy

Administrative Informations


NCT ID

NCT03848832

Organization ID

GWND18064

Secondary IDs

2018-003370-27

Responsible Party

Sponsor

Study Sponsor

Jazz Pharmaceuticals


Study Sponsor

, , 


Verification Date

December 2021